Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

ABOD2011 hos pasienter med avanserte solide svulster utviklet seg etter standard systemisk terapi

En åpen-blind doseeskaleringsstudie for å vurdere sikkerheten, toleransen og den foreløpige effekten av ABOD2011 hos pasienter med avanserte solide svulster etter standard systemisk terapi

Based on the activation and regulation of immune system by cytokines, mRNA encoding cytokines has become one of the important directions of mRNA tumor drug development. This product (ABOD2011) is a new generation mRNA product for intratumoral injection.

The primary objective of this study is to assess the safety and tolerability, of ABOD2011 in patients with advanced solid tumors that progressed after standard systemic therapy.

Studieoversikt

Studietype

Intervensjonell

Registrering (Faktiske)

20

Fase

  • Fase 1

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

      • Beijing, Kina
        • Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  1. 18 years and older.
  2. Understand and voluntarily sign the informed consent form (ICF).
  3. Histopathologically confirmed recurrent or metastatic solid tumors.
  4. Failure of prior systemic standard of care, or intolerance to severe toxicity, or lack of standard of care.
  5. Presence of at least one measurable lesion as assessed by RECIST Version 1.1.
  6. At least one superficial or deep lesion for intratumoral administration and biopsy.
  7. Sufficient organ functions.
  8. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1.
  9. Weight > 30 kg.
  10. Expected survival longer than 12 weeks.
  11. Evidence of menopause in female patients, or for women of childbearing potential: negative for urine or blood pregnancy.

Exclusion Criteria:

  1. Any systemic anti-tumor therapy, within 28 days prior to the first dose.
  2. Radiotherapy within 14 days prior to first dose.
  3. Use of immunosuppressants.
  4. Major surgery within 28 days.
  5. Inadequately controlled diseases.
  6. Active autoimmune and inflammatory diseases.
  7. Clinically symptomatic central nervous system tumors or metastases.
  8. Toxicity of prior anti-tumor therapy is still NCI-CTCAE ≥ 2.
  9. Other malignancies within the previous 5 years with the exception of cured basal cell carcinoma of the skin, superficial bladder cancer, carcinoma in situ of the breast, and carcinoma in situ of the cervix.
  10. Active infections.
  11. Other conditions that may increase the risk associated with the study drug, or affect the study compliance, etc., which, in the opinion of the investigator, are not suitable for participation in the study.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Ikke-randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Human single chain IL-12 mRNA-single dose

Human single chain IL-12 mRNA-single dose

human single chain IL-12 mRNA administered as specified in the treatment arm with injection once only

Eksperimentell: Human single chain IL-12 mRNA-multiple dose

Human single chain IL-12 mRNA-multiple dose

human single chain IL-12 mRNA administered as specified in the treatment arm with injection once per week for 3 weeks

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Number of Participants Experiencing dose-limiting toxicities (DLTs)
Tidsramme: From first dose to Day 28

Number of Participants Experiencing dose-limiting toxicities (DLTs)

From first dose to Day 28
Number of Participants Experiencing Adverse Events (AEs)
Tidsramme: From signed ICF until the date of last visit or start new antitumor therapy, whichever comes first, assessed up to 36 months

Number of Participants Experiencing Adverse Events (AEs)

From signed ICF until the date of last visit or start new antitumor therapy, whichever comes first, assessed up to 36 months
Number of Participants Experiencing Severe Adverse Events (SAEs)
Tidsramme: From signed ICF until the date of last visit or start new antitumor therapy, whichever came first, assessed up to 24 months

Number of Participants Experiencing Severe Adverse Events (SAEs)

From signed ICF until the date of last visit or start new antitumor therapy, whichever came first, assessed up to 24 months

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Overall Response Rate (ORR)
Tidsramme: Up to 36 months

Overall Response Rate (ORR)

Up to 36 months
Disease Control Rate(DCR)
Tidsramme: Up to 36 months

Disease Control Rate(DCR)

Up to 36 months
Duration of Response (DOR)
Tidsramme: Up to 36 months

Duration of Response (DOR)

Up to 36 months
Progression-Free Survival (PFS)
Tidsramme: Up to 36 months

Progression-Free Survival (PFS)

Up to 36 months
Overall Survival
Tidsramme: Up to 36 months

Overall Survival

Up to 36 months
Maximum observed concentration (Cmax) of ABOD2011
Tidsramme: From first dose of ABOD2011 through to 28 days after last dose of investigational product

Maximum observed concentration (Cmax) of ABOD2011

From first dose of ABOD2011 through to 28 days after last dose of investigational product
Area under the concentration-time curve (AUC) of ABOD2011
Tidsramme: From first dose of ABOD2011 through to 28 days after last dose of investigational product

Area under the concentration-time curve (AUC) of ABOD2011

From first dose of ABOD2011 through to 28 days after last dose of investigational product
Maximum observed concentration (Cmax) of IL-12
Tidsramme: From first dose of ABOD2011 through to 28 days after last dose of investigational product

Maximum observed concentration (Cmax) of IL-12

From first dose of ABOD2011 through to 28 days after last dose of investigational product
Area under the concentration-time curve (AUC) of IL-12
Tidsramme: From first dose of ABOD2011 through to 28 days after last dose of investigational product.

Area under the concentration-time curve (AUC) of IL-12

From first dose of ABOD2011 through to 28 days after last dose of investigational product.
Plasma concentration of IFN gamma
Tidsramme: From first dose of ABOD2011 through to 28 days after last dose of investigational product.

Plasma concentration of IFN gamma

From first dose of ABOD2011 through to 28 days after last dose of investigational product.

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Etterforskere

  • Hovedetterforsker: Ning Li, Doctor, Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

25. mai 2022

Primær fullføring (Faktiske)

9. desember 2023

Studiet fullført (Faktiske)

9. desember 2023

Datoer for studieregistrering

Først innsendt

15. mars 2022

Først innsendt som oppfylte QC-kriteriene

23. mai 2022

Først lagt ut (Faktiske)

26. mai 2022

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

2. oktober 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

29. september 2026

Sist bekreftet

1. juni 2022

Mer informasjon

Begreper knyttet til denne studien

Andre studie-ID-numre

  • ABOD2011-001

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere